BETAAccess all features while we're in beta! Some features may become paid later.Send feedback →
vpside

BMEA

Biomea Fusion, Inc.
Nasdaq · Pharmaceutical preparations (SIC 2834) · FY ends 31 Dec

Revenue, quarterly

$165M
$1.5B$1B$500M$0
Q3 ’21Q4 ’21Q1 ’22Q2 ’22Q3 ’22
Company filings · 10-Q filed 7 Nov 2022 · Q4 = FY − 9Mvpside.com

Gross margin, trailing twelve months

—
Not reported in this company’s filings
Company filingsvpside.com

Cash and cash equivalents, quarter-end

$35M−38.1% year on year
$300M$200M$100M$0
Q3 ’21Q4 ’22Q1 ’24Q1 ’25Q2 ’26
Company filings · 10-Q filed 5 Aug 2026 · balance sheet, period-endvpside.com

Free cash flow, trailing twelve months

−$87M
$50M$0−$50M−$100M−$150M
Q2 ’22Q1 ’23Q1 ’24Q4 ’24Q3 ’25
Company filings · 10-Q filed 4 Nov 2025 · TTM = last four quartersvpside.com
Chart 05 is empty
Chart 06 is empty